EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open‐label study

Michihiro Hide iD, Isao Ohsawa, Christina Nurse, Ming Yu, SHP643-302 Trial Investigators

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16909 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Michihiro Hide und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited, Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The safety and efficacy of lanadelumab for the prevention of hereditary angioedema (HAE) attacks have not been studied in Japanese patients. We report outcomes from a phase 3, multicenter, open‐label study (NCT04180163) of lanadelumab in Japanese patients with HAE. Japanese patients with HAE aged ≥12 years with ≥1 investigator‐confirmed HAE attack during the 4‐week run‐in baseline period were enrolled into the study and received lanadelumab 300 mg every 2 weeks subcutaneously for 52 weeks. Dosing could be reduced to 300 mg every 4 weeks during the second 26‐week treatment period if patients had well‐controlled symptoms (e.g., attack‐free) for 6 months. The primary efficacy endpoint was no investigator‐confirmed HAE attacks (attack‐free status) during days 0–182. Other outcomes included the rate of investigator‐confirmed HAE attacks per month (28 days) and lanadelumab safety. Twelve patients (mean ± SD age 41.9 ± 12.4 years) were enrolled. During the first 26 weeks (days 0–182), five (41.7%) patients were attack‐free. The mean ± SD HAE attack rate per month decreased by 74.0%, from 3.8 ± 2.4 during baseline to 1.2 ± 2.6 during the overall 52‐week treatment period. There were no deaths or discontinuations due to treatment‐emergent adverse events (TEAEs), no severe or serious TEAEs related to lanadelumab, and no positive anti‐drug antibody results. The most frequent TEAEs were injection‐site reactions (37 events in six patients). Most of the injection‐site reaction adverse events were mild in severity. Results of this study support the findings from two global phase 3 studies for lanadelumab use as prophylactic therapy in Japanese patients with HAE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryAntibodies, Monoclonal, HumanizedHumansComplement C1 Inhibitor ProteinEast Asian PeopleInjection Site ReactionTreatment OutcomeAdultMiddle Aged

Stichwörter der Autor:innen

Japanesehereditary angioedemalanadelumabprophylaxissubcutaneous injections

Substanzen

Antibodies, Monoclonal, HumanizedComplement C1 Inhibitor Proteinlanadelumab

Autor:innen und Institutionen

  • Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Department of Dermatology, Hiroshima University, Hiroshima, Japan.
  • Department of Nephrology, Internal Medicine, Saiyu Soka Hospital, Soka, Japan.
  • Department of Nephrology, Juntendo University Faculty of Medicine, Bunkyo-ku, Japan.
  • Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.

ORCID-Profile: Michihiro Hide

Förderung

  • Takeda Pharmaceutical Company Limited
  • Takeda Pharmaceutical Company

Zitieren

APA

Hide, M., Ohsawa, I., Nurse, C., Yu, M., & SHP643-302 Trial Investigators (2023). Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open‐label study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16909

Vancouver

Hide M, Ohsawa I, Nurse C, Yu M, SHP643-302 Trial Investigators. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open‐label study. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16909

BibTeX
@article{Hide2023,
  author = {Hide, Michihiro and Ohsawa, Isao and Nurse, Christina and Yu, Ming and SHP643-302 Trial Investigators, SHP643-302 Trial Investigators},
  title = {Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open‐label study},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16909}
}
Kostenlos starten →